GLP-3RT Mechanism of Action
Direct answer. Published cell assays show that LY3437943 activates the GLP-1, GIP and glucagon receptors. Cryo-EM structures show how the peptide makes shared contacts deep in the three receptor pockets while adapting to differences near their extracellular surfaces. GLP-3RT is Luxara’s catalogue name for material listed as LY3437943.[1] [2]
Key Takeaways
- Triple agonism describes the target profile. The three receptors are GLP-1R, GIPR and GCGR. Each has its own assay response.[1]
- Shared contacts anchor the peptide. Differences in receptor loops and side chains help explain how each complex accommodates it.[2]
- Identify the readout before comparing results. A cAMP response, a structural contact and a calculated interaction energy answer different questions.[2] [3] [4]
How receptor activation produces a cAMP signal
GLP-1R, GIPR and GCGR are class B1 G protein-coupled receptors. When an agonist engages one of these receptors, the activated receptor can couple to the stimulatory G protein, Gs. This promotes adenylyl cyclase activity and the formation of cyclic AMP (cAMP), an intracellular signalling molecule. The foundational LY3437943 study measured cAMP accumulation in cell systems expressing each receptor separately. It reported a GIPR preference in that experimental system.[1] [2]
Potency and maximal response describe different parts of the response curve. EC50 indicates the concentration corresponding to half of the fitted maximum for that response. Emax describes its maximum. Receptor expression, signal amplification and the reference ligand affect how those measures should be compared. Compare values in matched assay conditions where possible.[1] [3]
How the peptide engages each receptor
In Li and colleagues’ cryo-EM structures, the peptide forms a helix. Its amino-terminal segment reaches into the transmembrane pocket, and the portion nearer the extracellular surface contacts the outer receptor. The authors also changed individual receptor residues and measured how those changes affected the cAMP response.[2]
GLP-1 receptor (GLP-1R)
The GLP-1R model shows peptide Asp15 near receptor Arg299 in the second extracellular loop. Replacing Arg299 with alanine lowered the measured cAMP signalling potency in the study. The structure locates the contact and the functional assay shows that changing the residue affects the response.[2]
GIP receptor (GIPR)
The first extracellular loop, ECL1, has a more relaxed shape in the GIPR model than in the other two complexes. Replacing Arg196 in that loop with tyrosine substantially reduced cAMP signalling potency. The result supports a role for that loop in functional recognition of the peptide.[2]
Glucagon receptor (GCGR)
The GCGR model shows a contact between peptide Phe6 and receptor Tyr138. Replacing Tyr138 with alanine reduced cAMP signalling potency, while replacing it with leucine modestly increased potency. The two substitutions show how the functional result depends on the replacement side chain.[2]
Inspect the three receptor structures
| Receptor | PDB entry | Resolution |
|---|---|---|
| GLP-1R | 8YW3 | 2.68 Å |
| GIPR | 8YW4 | 3.26 Å |
| GCGR | 8YW5 | 2.84 Å |
These values describe the overall reconstructions. For an individual contact, inspect the local map and validation report. Li and colleagues reported several poorly resolved segments that were left out of the models.[2]
What each line of evidence can establish
Functional readouts
Dinsmore and colleagues’ 2025 Figure 5 includes LY3437943 in a GLP-1R comparison of cAMP signalling potency and maximal β-arrestin-2 recruitment. The two panels use different measures. To assess signalling bias, check the reference ligand and whether the study supports a comparison that accounts for assay amplification and the full response curves.[3]
2026 molecular modelling
Vishnoi and colleagues used the LY3437943 peptide backbone as a reference in simulations of the three receptors. Their model omitted the lipid conjugate. Its calculated enthalpies describe the modelled complexes and can guide hypotheses about molecular contacts. Use measured binding and functional assays to investigate affinity and response.[4]
Evidence reviewed through . See our research standards and methodology.
Check the identity and documentation of the research lot
The papers describe their own study material. For a Luxara lot, match the label to the corresponding entry in the laboratory results directory. Review the sample identifier and methods, then read the identity, chromatographic purity and measured content results individually when reported. The COA reading guide and Luxara Quality Standard explain what the documentation covers.
For supplier evaluation, lot traceability and Canadian fulfilment context, see Luxara’s Canadian peptide sourcing guide.
Continue your research
- GLP-3RT Research Hub — find primary papers and related documentation.
- GLP-3RT Canada Research Guide — review the compound profile.
- GLP-3RT vs GLP-2TZ — compare triple and dual receptor targeting.
- Luxara Research Index and Peptide Knowledge Hub — explore the wider research library.
Frequently asked questions
Does triple agonism mean equal activity at all three receptors?
Triple agonism means the peptide produced functional responses at three receptor types. To assess relative activity, read each receptor’s response curve, reference ligand and assay conditions.[1]
Why do the studies measure cAMP?
cAMP is a downstream signal associated with Gs activation. Its accumulation provides a functional readout in receptor-expressing cells. Direct binding assays address affinity.[1] [3]
What does receptor mutagenesis add to cryo-EM?
Cryo-EM shows the arrangement of a captured complex. Comparing responses after a receptor residue is changed helps assess that residue’s contribution to signalling in the assay.[2]
Which structure contains the glucagon receptor?
PDB 8YW5 contains LY3437943 bound to GCGR in a Gs complex. The reported overall resolution is 2.84 Å.
Sources and structural records
- Coskun et al. · Cell Metabolism · 2022. DOI 10.1016/j.cmet.2022.07.013. Foundational receptor pharmacology and cAMP assays.
- Li et al. · Cell Discovery · 2024. DOI 10.1038/s41421-024-00700-0. Receptor structures and functional mutagenesis. PDB entries 8YW3, 8YW4 and 8YW5.
- Dinsmore et al. · Journal of the American Chemical Society · 2025. DOI 10.1021/jacs.5c04095. GLP-1R signalling comparison in Figure 5.
- Vishnoi et al. · Journal of Computer-Aided Molecular Design · 2026. DOI 10.1007/s10822-026-00903-5. Reference peptide simulations and supporting dataset.